HCC

Ming Zhao, MD, explains the background of the FOHAIC-1 study.

During a Targeted Oncology case-based roundtable event, Richard S. Finn, MD, discussed the frontline treatment options for a patient with hepatocellular carcinoma.

Cabozantinib in combination with atezolizumab shows no effect on survival compared to sorafenib in patients with previously untreated advanced hepatocellular carcinoma based on results from the final analysis of the phase 3 COSMIC-312 trial.

During a live virtual event, Pierre Gholam, MD, discussed treatment options for a patient with hepatocellular carcinoma who had serious medical conditions including cirrhosis, Crohn's disease, and variceal bleeding.

Daneng Li, MD, discusses the results of the REFLECT trial of lenvatinib in hepatocellular carcinoma.

In an interview with Targeted Oncology™, Ming Zhao, MD, discusses the results of the FOHAIC-1 clinical trial and how it compares to HAIC-FO for the treatment of HCC.

Tanios S. Bekaii-Saab, MD, FACP, Richard S. Finn, MD, and William P. Harris, MD, highlight advances in research and clinical treatment of hepatocellular carcinoma over the past 10 years.

Patients with advanced hepatocellular carcinoma achieved notable improvements in survival and responses following treatment with transarterial chemoembolization and lenvatinib.

In subjects with recurrent hepatocellular carcinoma who underwent liver transplant, both progression-free survival and overall survival were prolonged with manageable adverse events.

The combination of transarterial chemoembolization, lenvatinib, and PD-1 checkpoint blockade demonstrated tolerable safety and efficacy in patients with unresectable advanced hepatocellular carcinoma.

In the phase 3 KEYNOTE-394 trial, pembrolizumab and best supportive care prolongs survival in patients.

Ghassan K. Abou-Alfa, MD, discusses the use of tislelizumab as treatment of patients with unresectable hepatocellular carcinoma, as investigated in a phase 2 clinical trial.

Although nivolumab did not significantly outperform sorafenib in the CheckMate 459 of patients with advanced hepatocellular carcinoma, positive resuls were shown for the secondary end points.

Closing out their discussion on the management of hepatocellular carcinoma, panelists discuss future novel therapies that may impact the treatment landscape.

Shifting their focus to the REFLECT trial of lenvatinib in unresectable hepatocellular carcinoma, panelists consider use of tyrosine kinase inhibition in this setting.

A panel of experts review data from the IMbrave150 trial of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma and consider implications for treatment.

Richard S. Finn, MD discusses a 77-year-old White woman who presented with complaints of abdominal pain and fatigue.

During a live virtual event, Richard S. Finn, MD, discussed the process of selecting frontline treatment for hepatocellular carcinoma including liver and kidney transplants and immunotherapy agents.

During a live virtual event, Richard S. Finn, MD, discussed the process of diagnosing liver cancer after a CT scan detected tumors and whether a biopsy was needed.

Lead investigator Arndt Vogel, MD, discussed the use of immunotherapy in earlier-stage HCC and findings from the IMMUTACE in an interview with Targeted Oncology.

Ghassan K. Abou-Alfa, MD, reviews the liver cancer landscape and the collaboration of Memorial Sloan Kettering Cancer Center with other institutions to further treatments in this setting.

A 77-year-old woman presented to her primary care physician with abdominal pain and fatigue.

The HIMALAYA study has met its primary end point of overall survival improvement in patients with unresectable hepatocellular carcinoma with tremelimumab plus durvalumab.

Arndt Vogel, MD, discusses the trial design of IMMUTACE, which is evaluating the efficacy of transarterial chemoembolization in combination with nivolumab for the treatment of intermediate-stage hepatocellular carcinoma.

Arndt Vogel, MD, the managing senior consultant and professor in the department of Gastroenterology, Hepatology, and Endocrinology, at the Hannover Medical School, discusses the real-world data of immunotherapy combinations in hepatocellular carcinoma.